8-K: BioRestorative Therapies Announces 1-for-20 Reverse Stock Split

BioRestorative Therapies, Inc. is implementing a 1-for-20 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

Summary

• BioRestorative Therapies, Inc. has approved a 1-for-20 reverse stock split of its common stock.
• This action is intended to regain compliance with the Nasdaq Capital Market's minimum bid price requirement of $1.00.
• The reverse stock split will be effective at 4:30 p.m. Eastern Time on September 7, 2026.
• Trading on a split-adjusted basis will commence on September 8, 2026, under the existing symbol BRTX and a new CUSIP number.
• The number of outstanding shares will decrease from approximately 27.6 million to 1.38 million.
• Authorized shares will be reduced proportionally from 1.5 billion to 75 million.
• Fractional shares will be rounded up to the nearest whole share.
• Adjustments will be made to stock options, warrants, and other equity awards.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development, as it indicates the company is struggling to maintain compliance with exchange listing requirements, a common sign of underlying financial or operational difficulties.

Positives

• Aims to regain compliance with Nasdaq's minimum bid price requirement, potentially avoiding delisting.
• No stockholder approval was required under Nevada law.
• Fractional shares will be rounded up, benefiting small shareholders who might otherwise receive no shares.
• Ownership percentages will remain unchanged, except for de minimis changes due to fractional share treatment.

Negatives

• The need for a reverse stock split often signals underlying issues with the company's stock performance and market perception.
• The company is at risk of non-compliance with Nasdaq listing standards if the stock price does not remain above $1.00 post-split.
• There's a risk of falling out of compliance with other Nasdaq requirements, such as minimum publicly held shares.
• Nasdaq rules may restrict further reverse stock splits within a one-year period.

Risks

• The reverse stock split may not result in a sustained increase in the stock price, leading to continued non-compliance or delisting.
• The stock price could decline below $1.00 again after the split.
• The company might fall out of compliance with other Nasdaq listing requirements.
• Market price volatility and trading volume of the common stock remain a concern.
• General business, economic, and market conditions could negatively impact the company.

Future Outlook

The company's future outlook is heavily dependent on its ability to maintain compliance with Nasdaq listing requirements following the reverse stock split. There is a stated intention to regain and maintain compliance with the $1.00 minimum bid price requirement, but the forward-looking statements acknowledge the risk that this may not be sustained.

Management Comments

• The Company is effecting the Reverse Stock Split with the intention of regaining compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).

Industry Context

StockSavvy.ai notes that reverse stock splits are often undertaken by companies facing delisting threats due to low stock prices. This is a common strategy to artificially boost the per-share price, but it does not address the underlying business fundamentals that led to the low price. For a late-stage clinical regenerative medicine company like BioRestorative Therapies, maintaining exchange listing is crucial for investor confidence and access to capital.

Stakeholder Impact

• Shareholders will hold fewer shares, but their proportional ownership interest will remain largely the same, except for fractional share adjustments.
• The reverse stock split is intended to benefit shareholders by preventing delisting from The Nasdaq Capital Market.
• Employees holding stock options or other equity awards will see adjustments to the number of shares and exercise prices.

Next Steps

• Monitor stock price to ensure sustained compliance with Nasdaq's minimum bid price requirement.
• Continue with clinical trials for BRTX-100 and the ThermoStem Program.
• Develop and sell cell-based biologic aesthetic products.

Key Dates

Recommendation

The reverse stock split is a defensive measure to maintain Nasdaq listing, not a sign of fundamental business improvement. While it addresses the immediate delisting risk, it does not resolve underlying operational or financial challenges. Investors should hold and await further developments regarding the company's clinical programs and ability to achieve sustainable profitability and market valuation.

Keywords

reverse stock split, Nasdaq compliance, stock performance, bid price, regenerative medicine, clinical trial, equity awards, Nevada law